No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients
- PMID: 21303629
- PMCID: PMC3045241
- DOI: 10.1177/193229681100500112
No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients
Abstract
Background: A strong relationship between glycemic variability and oxidative stress in poorly regulated type 2 diabetes (T2DM) on oral medication has been reported. However, this relationship was not seen in type 1 diabetes. The purpose of this study is to reexamine the relation between glycemic variability and oxidative stress in a cohort of T2DM patients on oral medication.
Methods: Twenty-four patients with T2DM on oral glucose lowering treatment underwent 48 hours of continuous glucose monitoring (CGMS® System GoldTM, Medtronic MiniMed) and simultaneous collection of two consecutive 24-hour urine samples for determination of 15(S)-8-iso-prostaglandin F2α (PGF2α) using high-performance liquid chromatography tandem mass spectrometry. Standard deviation (SD) and mean amplitude of glycemic excursions (MAGE) were calculated as markers of glycemic variability.
Results: Included in the study were 66.7% males with a mean age (range) of 59 (36-76) years and a mean (SD) HbA1c of 6.9% (0.7). Median [interquartile range (IQR)] urinary 15(S)-8-iso-PGF2α excretion was 176.1 (113.6-235.8) pg/mg creatinine. Median (IQR) SD was 31 (23-40) mg/dl and MAGE 85 (56-106) mg/dl. Spearman correlation did not show a significant relation for SD (ρ = 0.15, p = .49) or MAGE (ρ = 0.23, p = .29) with 15(S)-8-iso-PGF2α excretion. Multivariate regression analysis adjusted for age, sex, HbA1c, and exercise did not alter this observation.
Conclusions: We did not find a relevant relationship between glucose variability and 15(S)-8-iso-PGF2α excretions in T2DM patients well-regulated with oral medication that would support an interaction between hyperglycemia and glucose variability with respect to the formation of reactive oxygen species.
© 2010 Diabetes Technology Society.
Figures

Comment in
-
The need for identifying standardized indices for measuring glucose variability.J Diabetes Sci Technol. 2012 Jan 1;6(1):218-9; author reply 220-1. doi: 10.1177/193229681200600129. J Diabetes Sci Technol. 2012. PMID: 22401342 Free PMC article. No abstract available.
Similar articles
-
Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10. Clin Ther. 2011. PMID: 22078152 Clinical Trial.
-
Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.JAMA. 2006 Apr 12;295(14):1681-7. doi: 10.1001/jama.295.14.1681. JAMA. 2006. PMID: 16609090
-
Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes.Diabetologia. 2008 Jan;51(1):183-90. doi: 10.1007/s00125-007-0842-6. Epub 2007 Nov 10. Diabetologia. 2008. PMID: 17994218
-
CGMS and Glycemic Variability, Relevance in Clinical Research to Evaluate Interventions in T2D, a Literature Review.Front Endocrinol (Lausanne). 2021 Sep 9;12:666008. doi: 10.3389/fendo.2021.666008. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34566883 Free PMC article. Review.
-
Assessing glycemic control with self-monitoring of blood glucose and hemoglobin A(1c) measurements.Mayo Clin Proc. 2007 Feb;82(2):229-35; quiz 236. doi: 10.4065/82.2.229. Mayo Clin Proc. 2007. PMID: 17290732 Review.
Cited by
-
Clinical Implications of Glucose Variability: Chronic Complications of Diabetes.Endocrinol Metab (Seoul). 2015 Jun;30(2):167-74. doi: 10.3803/EnM.2015.30.2.167. Endocrinol Metab (Seoul). 2015. PMID: 26194076 Free PMC article. Review.
-
Heterogeneity of Metabolic Defects in Type 2 Diabetes and Its Relation to Reactive Oxygen Species and Alterations in Beta-Cell Mass.Front Physiol. 2019 Feb 13;10:107. doi: 10.3389/fphys.2019.00107. eCollection 2019. Front Physiol. 2019. PMID: 30837889 Free PMC article. Review.
-
Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications.Cardiovasc Diabetol. 2021 Jan 7;20(1):9. doi: 10.1186/s12933-020-01200-7. Cardiovasc Diabetol. 2021. PMID: 33413392 Free PMC article. Review.
-
Independent Association of Glucose Variability With Hospital Mortality in Adult Intensive Care Patients: Results From the Australia and New Zealand Intensive Care Society Centre for Outcome and Resource Evaluation Binational Registry.Crit Care Explor. 2019 Aug 1;1(8):e0025. doi: 10.1097/CCE.0000000000000025. eCollection 2019 Aug. Crit Care Explor. 2019. PMID: 32166267 Free PMC article.
-
Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications.J Diabetes Res. 2020 Oct 12;2020:7489795. doi: 10.1155/2020/7489795. eCollection 2020. J Diabetes Res. 2020. PMID: 33123598 Free PMC article. Review.
References
-
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986. - PubMed
-
- Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–820. - PubMed
-
- The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–983. - PubMed
-
- Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005;19(3):178–181. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical